ClinicalTrials.gg
CompletedNCT06880081Updated Oct 21, 2026

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

A Phase 1 interventional study of PN20 treatment in Primary Immune Thrombocytopenia (ITP), sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Completed at 5 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Updated Oct 21, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 84 open to participants now, 94 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Enrollment
151st of 169
12 · median 60
Started
2025
with 26 others
Phase 1
21 of 187
12 open now
Registered
147th of 187
by date

Among the 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 151st largest by enrollment of the 169 interventional ones that give a count, is one of 27 that started in 2025, is one of 21 in phase 1, and was the 147th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

84 of the 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with primary immune thrombocytopenia (ITP). The main questions it aims to answer are:

  • Is PN20 safe in these patients?
  • Could these patients potentially benefit from PN20 treatment?

Participants will

  • Receive one subcutaneous injection of PN20 according to weight;
  • Visit the clinic for assessment.
Read the detailed description

This is a multicenter, open-label, single-arm, dose-escalation Phase1b study aimed at evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of a single dose of PN20 in adult patients with primary immune thrombocytopenia (ITP).

The trial is a dose escalation study, including Screening (no more than 14 days), Treatment (single dose) and the post-treatment follow-up (4 weeks).

And the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of PN20 in ITP will be assessed in this study.

03

Conditions studied

  • Primary Immune Thrombocytopenia (ITP)

Keywords

  • Primary Immune Thrombocytopenia (ITP)
  • thrombopoietin receptor agonist
  • PN20
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Aged between 18 and 65 years (inclusive), male or female;
  2. Diagnosed with primary immune thrombocytopenia (ITP) and have a disease course of more than 6 months;
  3. Patients who have no response or after splenectomy. Or patients who have not been splenectomised and have completed at least 1 prior treatment for ITP (such as , immunoglobulin) and have failed to respond or relapsed after treatment;
  4. During screening period, the mean of two counts must be \< 30 × 10\^9/L, with none >35 × 10\^9/L;
  5. Fully understand and are able to comply with the requirements of the protocol, voluntarily participate and sign the form.

Key Exclusion Criteria:

  1. History of bone marrow stem cell disorder. Any abnormal bone marrow findings other than typical of ITP.
  2. Any active . If prior history of cancer other than basal cell carcinoma or cervical carcinoma in situ, no treatment or active disease within 5 years prior to signing the ICF.
  3. Diagnosed with arterial thrombotic disease (such as cerebral thrombosis, , myocardial infarction, peripheral arterial disease, etc.); Patients with a history or complications of venous thrombosis (such as deep vein thrombosis, pulmonary embolism); or patients who are using anticoagulants or antiplatelet drugs at the beginning of screening.
  4. Subjects who have used romiplostim or its analogs in the past and have not responded.
  5. Subjects who have used eltrombopag, haitubopag, avatubopag, recombinant human thrombopoietin (rhTPO), or other drugs with c-MPl stimulating effects within the 4 weeks prior to signing the ICF.
  6. Received any anti-malignancy agents (e.g., cyclophosphamide, mercaptopurine, vincristine, vinblastine, interferon-alfa) within 8 weeks prior to signing the ICF.
  7. Less than 4 weeks since end of any clinical trials about therapeutic drug or device prior to signing the ICF.
  8. Laboratory abnormalities with clinical significance at screening visit.
  9. In the opinions of investigators, the patients are not suitable for participation in this trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    PN20 treatment group-single dose

    A single dose of PN20 will be administered.

    Drug: PN20 treatment

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Event (AE)

    The incidence of adverse events related to PN20.

    Time frame: Treatment and post-treatment follow-up period (28 days after a single dose)

Secondary outcomes

  1. The percentage of subjects who reach the target therapeutic platelet level after administration

    It is defined as the proportion of subjects whose platelet count reaches at least 2 times the baseline platelet count within 28 days after administration and is within the range of 50×10\^9/L to 450×10\^9/L (inclusive).

    Time frame: Treatment and post-treatment follow-up period (28 days after a single dose)

07

Study locations

5 sites
  • Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou 550004, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Jining First People's Hospital
    Jining, Shandong 272011, China
  • Hematology Hospital of Chinese Academy of Medical Sciences
    Tianjin, Tianjin Municipality 301609, China
  • The Second Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Feb 2026, 11 months.

Of 27 phase 1 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's 11 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Apr 2026 → Feb 2026, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 17, 2025
StartActual
Mar 7, 2025
Primary completionActual
Feb 14, 2026
CompletionActual
Feb 14, 2026was Apr 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 21, 2026
Primary completion
Feb 27, 2026→Feb 14, 2026 (actual)
Oct 21, 2026
Study completion
Apr 28, 2026→Feb 14, 2026 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Completed
    Primary completion Feb 27, 2026→Feb 14, 2026 (now actual)
    Study completion Apr 28, 2026→Feb 14, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06880081
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Mar 7, 2025
Primary completion
Feb 14, 2026
Completion
Feb 14, 2026
Last update
Oct 21, 2026

Study contacts

Lei Zhang
principal investigator · Chinese Academy of Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thrombopoietin Receptor Agonist

Start the discussion